Repatha®
evolocumab injection

Dosing options for your adult Repatha® patients

Biweekly or once monthly

The recommended dose for Repatha® (prevention of cardiovascular events and primary hyperlipidemia) is either 140 mg every 2 weeks (Q2W) or 420 mg once monthly (QM)[1]

Q2W and QM doses are clinically equivalent[1]

Repatha® 140 mg Q2W[1]

Self-administered injection Q2W with single-use prefilled SureClick® autoinjector

- Hidden 27-gauge needle[2]
- Delivers the 140 mg dose subcutaneously in about 15 seconds[1]
- Consider for patients who are comfortable self-injecting with a hand-held device

NEW!

Injection duration is now reduced to ~5 minutes (from 9 minutes)

Repatha® 420 mg QM[1]

Self-administered injection QM with single-use automated mini-doser (AMD)

- Hidden 29-gauge needle[2]
- Delivers the 420 mg dose subcutaneously in about 5 minutes[1]
- Moderate physical activities can be performed during the injection process, such as walking, reaching and bending[1]

Repatha® is intended for patient self-administration after proper training. Administration should be performed by an individual who has been trained to administer the product.

Repatha® can be stored at room temperature for up to 30 days.[1]

As standard practice, Repatha® should be stored in the refrigerator (2°C to 8°C). If removed from the refrigerator, Repatha® should be kept at controlled room temperature up to 25°C in the original carton and must be used within 30 days. Protect from direct light and temperatures above 25°C. Do not freeze. Do not shake.

No dose adjustment required for:[1]

- Geriatric patients
- Patients with mild to moderate renal impairment
- Patients with mild to moderate hepatic impairment

Patients with severe or end-stage renal disease (ESRD) receiving hemodialysis: there is limited experience with Repatha® in these patients. No dosage adjustment may be required.[1]

Patients with severe renal impairment: Repatha® should be used with caution.[1]

No statin dose adjustments are necessary when used in combination with Repatha®.[1]

Please see the Product Monograph for complete dosing and drug interaction information.

RepathaREADY® PATIENT SUPPORT PROGRAM

YOUR PARTNER IN CARE, EVERY STEP OF THE WAY

by AMGEN Entrust™ Patient Support Services*

Injection training provided: Repatha® SureClick autoinjector and automated mini-doser (AMD)

Indications and clinical use:

Repatha® (evolocumab injection) is indicated:

- as an adjunct to diet and standard of care therapy (including moderate- to high-intensity statin therapy alone or in combination with other lipid-lowering therapy) to reduce the risk of myocardial infarction, stroke and coronary revascularization in adult patients with atherosclerotic cardiovascular disease (ASCVD) by further lowering low-density lipoprotein cholesterol (LDL-C) levels.
- for the reduction of elevated LDL-C in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia [HeFH] and ASCVD):
  - as an adjunct to diet and statin therapy, with or without other lipid-lowering therapies, in patients who require additional lowering of LDL-C
  - as an adjunct to diet, alone or in combination with non-statin lipid-lowering therapies, in patients for whom a statin is contraindicated.

Contraindications:

- Hypersensitivity to Repatha® or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container
- Refer to the Contraindications section of the relevant product monographs of any concomitant lipid-lowering medications

Relevant warnings and precautions:

- Refer to the Warnings and Precautions section of the relevant product monographs of any concomitant lipid-lowering medications
- Hypersensitivity reactions (e.g., rash, urticaria, angioedema) have been reported. If signs or symptoms of serious allergic reactions occur, discontinue Repatha® and treat according to standard of care and monitor until signs and symptoms resolve
- No studies have been conducted with Repatha® in pregnant women or nursing women and relevant data from clinical use are very limited
- There is no information regarding the presence of evolocumab in human milk, the effects on the breastfed infant, or the effects on milk production; a risk to breastfed infants cannot be excluded
- Statin product monographs recommend discontinuation when a patient becomes pregnant, therefore Repatha® should also be discontinued
- Data on efficacy and safety in HoFH patients aged 10-11 years are limited
- Efficacy and safety have not been established in pediatric patients <10 years of age with HeFH, HoFH or in pediatric patients with other types of hyperlipidemia
- Use with caution in patients with severe renal impairment
- Use with caution in patients with severe hepatic impairment
- Needle cap of the SureClick autoinjector contains dry natural rubber, which may cause an allergic reaction in latex-sensitive patients; there is no dry natural rubber in the automated mini-doser with prefilled cartridge
- Effects of Repatha® in patients with or at risk of hepatitis C virus infection remain uncertain

For more information:

Consult the Product Monograph at www.amgen.ca/products/~/media/AE162719487C459391BD1B1584A25EAD.ashx for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this piece.

The Product Monograph is also available by calling Amgen Medical Information at 1-866-502-6436.

Repatha® is intended for patient self-administration after proper training. Administration should be performed by an individual who has been trained to administer the product.

* AMGEN Entrust is our unified patient support services platform, built on the legacy of our branded support programs.

References: 1. Repatha® (evolocumab injection) Product Monograph. Amgen Canada Inc., December 9, 2021. **2.** Amgen Canada. Data on File letter.

Repatha® evolocumab injection

AMGEN Entrust™ RepathaREADY®

REVIEWED BY PAAB

MEMBER OF INNOVATIVE MEDICINES CANADA

AMGEN® Cardiovascular

EVO-0045E-21